Biophytis S.A. (LON: 0D1W)
London
· Delayed Price · Currency is GBP · Price in EUR
0.302
-0.008 (-2.45%)
At close: Jan 22, 2025
Biophytis Employees
Biophytis had 22 employees as of December 30, 2023. The number of employees decreased by 2 or -8.33% compared to the previous year.
Employees
22
Change (1Y)
-2
Growth (1Y)
-8.33%
Revenue / Employee
n/a
Profits / Employee
-580.91K GBP
Market Cap
4.06M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
Shell | 103,000 |
HSBC Holdings | 220,861 |
Unilever | 128,377 |
Rio Tinto Group | 57,000 |
RELX PLC | 36,500 |
BP p.l.c. | 87,800 |
British American Tobacco p.l.c. | 46,725 |
Biophytis News
- 4 months ago - Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities - Accesswire
- 6 months ago - Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia - Accesswire
- 7 months ago - Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity - Accesswire
- 7 months ago - Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris - Accesswire
- 7 months ago - Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million - Accesswire
- 7 months ago - Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities - Accesswire
- 8 months ago - Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens - Accesswire
- 8 months ago - Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity - Accesswire